Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Gregory A. Nemeth"'
Autor:
Jian Shen, Jiping Yang, Winfried Heyse, Harald Schweitzer, Norbert Nagel, Doris Andert, Chengyue Zhu, Vincent Morrison, Gregory A. Nemeth, Teng-Man Chen, Zhicheng Zhao, Timothy A. Ayers, Yong-Mi Choi
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Otamixaban is a potent (Ki=0.5Â nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric chara
Externí odkaz:
https://doaj.org/article/e216df50786d432c972e05ee222dd331
Publikováno v:
SLAS technology. 23(5)
We describe a custom Internet of Things (IoT) device used for tracking barcoded containers end to end in a high-throughput analysis and purification laboratory. Our IoT device fills an important gap that previously prevented us from fully tracking ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871a773efb562807e6cb2cb3407d55d5
https://pubmed.ncbi.nlm.nih.gov/30016131
https://pubmed.ncbi.nlm.nih.gov/30016131
Autor:
Jiping Yang, Jian Shen, Winfried Heyse, Doris Andert, Harald Schweitzer, Chengyue Zhu, Gregory A. Nemeth, Yong-Mi Choi, Zhicheng Zhao, Timothy A. Ayers, Vincent Morrison, Teng-Man Chen, Norbert Nagel
Publikováno v:
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Journal of Pharmaceutical Analysis, Vol 4, Iss 3, Pp 197-204 (2014)
Otamixaban is a potent (Ki=0.5Â nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286fd0572070c3d598a63939b6535cd2
Autor:
C. M. Foris, Shelley R. Rabel, G. Creston Campbell, Gregory A. Nemeth, Susan M. Rowe, Michael B. Maurin, J. Gerry Everlof, Rodney Vickery
Publikováno v:
Journal of Pharmaceutical Sciences. 91:2599-2604
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state carbon nuclear magnetic resonance. A slight difference between the two polymorphs was also detected by isothermal microcal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eced34e748fdc6094b327cf22de55d9
https://doi.org/10.1002/jps.10078
https://doi.org/10.1002/jps.10078
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 30:125-129
Roxifiban, an experimental antithrombotic prodrug, exists as crystalline forms I and II. A quantitative solid-state nuclear magnetic resonance (NMR) method was developed to characterize the two polymorphs of roxifiban. The differences in the NMR spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e65c38d4a0fa565f4c39cc0ebda8198
https://doi.org/10.1016/s0731-7085(02)00203-0
https://doi.org/10.1016/s0731-7085(02)00203-0
Publikováno v:
Journal of biomolecular screening. 20(5)
High-performance liquid chromatography (HPLC) biogram methodology is a powerful pharmaceutical screening hit confirmation strategy that couples analytical HPLC data with functional bioassay data. It is used primarily for screening hit chemical valida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811234c638846e212ffd38f4aa3e5399
https://pubmed.ncbi.nlm.nih.gov/25681433
https://pubmed.ncbi.nlm.nih.gov/25681433
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 24:681-687
DMP 504, a potential bile acid sequestrant for the treatment of hypercholesterolemia, is a highly insoluble, cross-linked polymer which does not lend itself to ordinary means of characterization used for drug substances in the pharmaceutical industry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0456401638bd54a33558ffb84ab7967
https://doi.org/10.1016/s0731-7085(00)00470-2
https://doi.org/10.1016/s0731-7085(00)00470-2
Publikováno v:
Pharmaceutical Development and Technology. 1:231-238
The purpose of this research was to enhance the aqueous solubility of DMP 840 by complexation with water-soluble and nontoxic agents, and to understand the nature of the interactions involved in complex formation using nuclear magnetic resonance (1H-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92abefe41649d4d7dea70fb685420e46
https://doi.org/10.3109/10837459609022591
https://doi.org/10.3109/10837459609022591
Autor:
Munir A. Hussain, Gregory A. Nemeth, Thomas H. Scholz, Krishnaswamy S. Raghavan, David B. Gray
Publikováno v:
Pharmaceutical Research. 13:1815-1820
Purpose. The objective was to evaluate the degradation profile of the elastase inhibitor DMP 777 and lay the foundation for formulation development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0211b821c24ae639505e08bc7d7cb031
https://doi.org/10.1023/a:1016076907072
https://doi.org/10.1023/a:1016076907072
Autor:
G.Creston Campbell, Krishnaswamy S. Raghavan, Anil Dwivedi, Munir A. Hussain, Gregory A. Nemeth
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 12:777-785
DuP 747, a selective kappa agonist analgesic, was found to have at least two polymorphic forms, and this was confirmed by X-ray powder diffraction. DSC and thermomicroscopic studies indicated the polymorphic pair to be monotropic. Solubility studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78c4454d50ed2c5ae19eace075bfa15
https://doi.org/10.1016/0731-7085(94)e0002-i
https://doi.org/10.1016/0731-7085(94)e0002-i